NEW YORK, April 04, 2026 (GLOBE NEWSWIRE) —
WHY: Rosen Regulation Agency, a worldwide investor rights regulation agency, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the essential April 14, 2026 lead plaintiff deadline.
SO WHAT: In case you bought REGENXBIO securities throughout the Class Interval you could be entitled to compensation with out fee of any out of pocket charges or prices by way of a contingency charge association.
WHY ROSEN LAW: We encourage buyers to pick out certified counsel with a observe document of success in management roles. Usually, corporations issuing notices don’t have comparable expertise, assets, or any significant peer recognition. Many of those corporations don’t truly deal with securities class actions, however are merely middlemen that refer shoppers or companion with regulation corporations that truly litigate the instances. Be smart in deciding on counsel. The Rosen Regulation Agency represents buyers all through the globe, concentrating its observe in securities class actions and shareholder spinoff litigation. Rosen Regulation Agency has achieved, at the moment, the most important ever securities class motion settlement towards a Chinese language Firm. Rosen Regulation Agency was Ranked No. 1 by ISS Securities Class Motion Providers for variety of securities class motion settlements in 2017. The agency has been ranked within the prime 4 every year since 2013 and has recovered a whole bunch of thousands and thousands of {dollars} for buyers. In 2019 alone the agency secured over $438 million for buyers. In 2020, founding companion Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Lots of the agency’s attorneys have been acknowledged by Lawdragon and Tremendous Attorneys.
DETAILS OF THE CASE: In accordance with the lawsuit, defendants offered buyers with materials info regarding REGENXBIO’s plan to develop and commercialize its product candidate RGX-111, a one-time gene remedy for the therapy of extreme Mucopolysaccharidosis Sort I, also referred to as Hurler syndrome. Defendants’ statements included, amongst different issues, REGENXBIO’s optimistic assertions of RGX-111’s future trial success based mostly on persevering with optimistic biomarker and security information from the continuing PhaseI/II examine. Defendants offered these overwhelmingly optimistic statements to buyers whereas, on the identical time, disseminating false and deceptive statements and/or concealing materials antagonistic information regarding the efficacy and security of its RGX-111 trial examine. When the true particulars entered the market, the lawsuit claims that buyers suffered damages.
More Read
No Class Has Been Licensed. Till a category is licensed, you aren’t represented by counsel until you keep one. You could choose counsel of your alternative. You may additionally stay an absent class member and do nothing at this level. An investor’s capacity to share in any potential future restoration will not be dependent upon serving as lead plaintiff.
Lawyer Promoting. Prior outcomes don’t assure an analogous final result.
——————————-
More Read
Contact Data:
